Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Bates Website

Susan Bates, M.D.

Selected Publications

1)  Luchenko VL, Litman T, Chakraborty AR, Heffner A, Devor C, Wilkerson J, Stein W, Robey RW, Bangiolo L, Levens D, Bates SE.
Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin.
Mol Oncol. [Epub ahead of print], 2014.
2)  Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet J, Kossenkov AV, Wilkerson J, Showe LC, Gottesman MM, Collie NL, Bates SE.
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with a MEK inhibitor.
Blood. 121: 4115-25, 2013.
3)  Noonan AM, Eisch RA, Liewehr DJ, Sissung TM, Venzon DJ, Flagg TP, Haigney MC, Steinberg SM, Figg WD, Piekarz RL, Bates SE.
Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
Clin. Cancer Res. 19: 3095-104, 2013.
4)  Basseville A, Tamaki A, Ierano C, Trostel S, Ward Y, Robey RW, Hegde RS, Bates SE.
Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter.
Cancer Res. 72: 3642-51, 2012.
5)  Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE.
Phase II trial of romidepsin in patients with peripheral T-cell lymphoma.
Blood. 117:: 5827-34, 2011.
6)  Fojo AT, Bates SE.
Clinical trial results: a clinical trial bazaar!.
Oncologist. 19: 313-4, 2014.
7)  Burotto M, Wilkerson J, Stein W, Motzer R, Bates S, Fojo T.
Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.
PLoS ONE. 9: e96316, 2014.
8)  Rubin EH, Allen JD, Nowak JA, Bates SE.
Developing precision medicine in a global world.
Clin. Cancer Res. 20: 1419-27, 2014.
9)  Bates SE.
It"s All About the Test: The Complexity of Companion Diagnostic Co-development in Personalized Medicine.
Clin. Cancer Res. 20: 1418, 2014.
10)  Zhang H, Kathawala RJ, Wang Y, Zhang Y, Patel A, Shukla S, Robey RW, Talele TT, Ashby CR, Ambudkar SV, Bates SE, Fu L, Chen Z.
Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.
Int. J. Biochem. Cell Biol. 51: 111-9, 2014.
11)  Bates SE.
The language of pharmacodynamics.
Clin. Cancer Res. 20: 2524, 2014.
12)  Bates SE.
A sea change in melanoma.
Clin. Cancer Res. 19: 5282, 2013.
13)  Fojo AT, Bates SE, Chabner BA.
Clinical trial results: sharing results, speeding discoveries.
Oncologist. 18: 779, 2013.
14)  Ierano C, Basseville A, To KK, Zhan Z, Robey RW, Wilkerson J, Bates SE, Scala S.
Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration.
Cancer Biol. Ther. 14: 175-83, 2013.
15)  Ierano C, Chakraborty AR, Nicolae A, Bahr JC, Zhan Z, Pittaluga S, Bates SE, Robey RW.
Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors.
Cell Cycle. 12: 2829-38, 2013.
16)  Fojo T, Bates S.
Mechanisms of resistance to PARP inhibitors--three and counting.
Cancer Discov. 3: 20-3, 2013.
17)  Bates SE.
On masterpieces and breast cancer research.
Clin. Cancer Res. 19: 6352, 2013.
18)  Bakhsheshian J, Hall MD, Robey RW, Herrmann MA, Chen J, Bates SE, Gottesman MM.
Overlapping Substrate and Inhibitor Specificity of Human and Murine ABCG2.
Drug Metab. Dispos. 41: 1805-12, 2013.
19)  Bates SE.
PFS: the endpoint we love and love to hate.
Clin. Cancer Res. 19: 2606, 2013.
20)  Amiri-Kordestani L, Luchenko V, Peer CJ, Ghafourian K, Reynolds J, Draper D, Frye R, Woo S, Venzon D, Wright J, Skarulis M, Figg WD, Fojo T, Bates SE, Piekarz RL.
Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers.
Clin. Cancer Res. 19: 4499-507, 2013.
21)  Blagoev KB, Wilkerson J, Stein WD, Motzer RJ, Bates SE, Fojo AT.
Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma.
Cell Rep. 3: 277-81, 2013.
22)  Jakopovic M, Thomas A, Balasubramaniam S, Schrump D, Giaccone G, Bates SE.
Targeting the Epigenome in Lung Cancer: Expanding Approaches to Epigenetic Therapy.
Front Oncol. 3: 261, 2013.
23)  Bates SE.
Waking the immune system at last.
Clin. Cancer Res. 19: 996, 2013.
24)  Harrison SJ, Bishton M, Bates SE, Grant S, Piekarz RL, Johnstone RW, Dai Y, Lee B, Araujo ME, Prince HM.
A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)).
Epigenomics. 4: 571-89, 2012.
25)  Bates SE.
A millennium goal for cancer.
Clin. Cancer Res. 18: 606, 2012.
26)  Kelly RJ, Robey RW, Chen CC, Draper D, Luchenko V, Barnett D, Oldham RK, Caluag Z, Frye AR, Steinberg SM, Fojo T, Bates SE.
A Pharmacodynamic Study of the P-glycoprotein Antagonist CBT-1(R) in Combination With Paclitaxel in Solid Tumors.
Oncologist. 17: 512, 2012.
27)  Stein WD, Wilkerson J, Kim ST, Huang X, Motzer RJ, Fojo AT, Bates SE.
Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth.
Clin. Cancer Res. 18: 2374-81, 2012.
28)  Moitra K, Im K, Limpert K, Borsa A, Sawitzke J, Robey R, Yuhki N, Savan R, Huang da W, Lempicki RA, Bates S, Dean M.
Differential gene and microRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines.
PLoS ONE. 7: e45268, 2012.
29)  Bates SE, Amiri-Kordestani L, Giaccone G.
Drug development: portals of discovery.
Clin. Cancer Res. 18: 23-32, 2012.
30)  Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, Gottesman MM.
Drug resistance: Still a daunting challenge to the successful treatment of AML.
Drug Resist. Updat. 15: 62-9, 2012.
31)  Fojo T, Bates S, Chabner BA.
Editor"s Note ...Clinical Trial Reports: A New Section.
Oncologist. 17: 11-2, 2012.
32)  Wang C, Liu Z, Woo CW, Li Z, Wang L, Wei JS, Marquez VE, Bates SE, Jin Q, Khan J, Ge K, Thiele CJ.
EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.
Cancer Res. 72: 315-24, 2012.
33)  Akilov OE, Grant C, Frye R, Bates S, Piekarz R, Geskin LJ.
Low-Dose Electron Beam Radiation and Romidepsin Therapy for Symptomatic Cutaneous T-Cell Lymphoma Lesions.
British J Dermatol. 167: 194-7, 2012.
34)  Zhang M, Mathur A, Zhang Y, Xi S, Atay S, Hong JA, Datrice N, Upham T, Kemp CD, Ripley RT, Wiegand G, Avital I, Fetsch P, Mani H, Zlott D, Robey R, Bates SE, Li X, Rao M, Schrump DS.
Mithramycin Represses Basal and Cigarette Smoke-Induced Expression of ABCG2 and Inhibits Stem Cell Signaling in Lung and Esophageal Cancer Cells.
Cancer Res. 72:: 4178-92, 2012.
35)  Bates SE.
Molecular diagnostics: are we there yet?.
Clin. Cancer Res. 18: 1514, 2012.
36)  Bates SE.
On drug development, chance, and the prepared mind.
Clin. Cancer Res. 18: 22, 2012.
37)  Bates SE.
Pancreatic cancer: steps in the right direction.
Clin. Cancer Res. 18: 4248, 2012.
38)  Bates SE.
Progress in pediatric cancer.
Clin. Cancer Res. 18: 2734, 2012.
39)  Bates SE.
Reinventing cancer cell metabolism.
Clin. Cancer Res. 18: 5536, 2012.
40)  Frye R, Myers M, Axelrod KC, Ness EA, Piekarz RL, Bates SE, Booher S.
Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma.
Clin J Oncol Nurs. 16: 195-204, 2012.
41)  Amiri-Kordestani L, Basseville A, Kurdziel K, Fojo AT, Bates SE.
Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies.
Drug Resist. Updat. 15: 50-61, 2012.
42)  Sissung TM, Troutman SM, Campbell TJ, Pressler HM, Sung H, Bates SE, Figg WD.
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Discov Med. 13: 19-34, 2012.
43)  Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, Chen X, Gardner ER, Balis FM, Venkatesan AM, Steinberg SM, Fojo T, Bates SE.
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.
Clin. Cancer Res. 17: 569-80, 2011.
44)  Bates SE.
Antibody conjugates: the future is now.
Clin. Cancer Res. 17: 6388, 2011.
45)  Versiani MA, Diyabalanage T, Ratnayake R, Henrich CJ, Bates SE, McMahon JB, Gustafson KR.
Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2.
J. Nat. Prod. 74: 262-6, 2011.
46)  Basseville A, Bates SE.
Gout, genetics and ABC transporters.
F1000 Biol Rep. 3: 23, 2011.
47)  Robey RW, Chakraborty AR, Basseville A, Luchenko V, Bahr J, Zhan Z, Bates SE.
Histone deacetylase inhibitors: emerging mechanisms of resistance.
Mol. Pharm. 8: 2021-31, 2011.
48)  Sissung TM, Gardner ER, Piekarz RL, Howden R, Chen X, Woo S, Franke R, Clark JA, Miller-DeGraff L, Steinberg SM, Venzon D, Liewehr D, Kleeberger SR, Bates SE, Price DK, Rosing DR, Cabell C, Sparreboom A, Figg WD.
Impact of ABCB1 allelic variants on QTc interval prolongation.
Clin. Cancer Res. 17: 937-46, 2011.
49)  Bates SE.
Multiple myeloma.
Clin. Cancer Res. 17: 1224, 2011.
50)  Fojo T, Amiri-Kordestani L, Bates SE.
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.
J. Natl. Cancer Inst. 103: 1738-40, 2011.
51)  Bates SE.
Prostate cancer: score one for validated targets.
Clin. Cancer Res. 17: 3866, 2011.
52)  Luchenko VL, Salcido CD, Zhang Y, Agama K, Komlodi-Pasztor E, Murphy RF, Giaccone G, Pommier Y, Bates SE, Varticovski L.
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
Cell Cycle. 10: 3119-28, 2011.
53)  Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng X, Abraham I, Ambudkar SV, Talele TT, Fu LW, Chen ZS.
Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance.
Cancer Res. 71: 3029-41, 2011.
54)  Arnaud O, Boumendjel A, Gèze A, Honorat M, Matera EL, Guitton J, Stein WD, Bates SE, Falson P, Dumontet C, Di Pietro A, Payen L.
The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.
Eur. J. Cancer. 47: 640-8, 2011.
55)  Robey RW, Ierano C, Zhan Z, Bates SE.
The Challenge of Exploiting ABCG2 in the Clinic.
Curr Pharm Biotechnol. 12: 595-608, 2011.
56)  Tamaki A, Ierano C, Szakacs G, Robey RW, Bates SE.
The controversial role of ABC transporters in clinical oncology.
Essays Biochem. 50: 209-32, 2011.
57)  Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, Ning YM, Arlen PM, Price D, Bates SE, Fojo T.
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.
Clin. Cancer Res. 17: 907-17, 2011.
58)  To KK, Robey R, Zhan Z, Bangiolo L, Bates SE.
Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway.
Mol. Cancer Res. 9: 516-27, 2011.
59)  Huang H, Menefee M, Edgerly M, Zhuang S, Kotz H, Poruchynsky M, Huff LM, Bates S, Fojo T.
A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.
Clin. Cancer Res. 16: 1634-41, 2010.
60)  Robey RW, Massey PR, Amiri-Kordestani L, Bates SE.
ABC transporters: unvalidated therapeutic targets in cancer and the CNS.
Anticancer Agents Med Chem. 10: 625-33, 2010.
61)  Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE.
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib and dasatinib.
Drug Metab Dispos. 38: 1371-80, 2010.
62)  Bates SE.
DNA repair: a reinvigorated therapeutic target.
Clin. Cancer Res. 16: 4510, 2010.
63)  Smith NF, Mani S, Schuetz EG, Yasuda K, Sissung TM, Bates SE, Figg WD, Sparreboom A.
Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.
Ann Pharmacother. 44: 1709-17, 2010.
64)  Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, Robey RW, Turner M, Gardner ER, Figg WD, Steinberg SM, Ling A, Fojo T, To KW, Piekarz RL.
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma.
Br. J. Haematol. 148: 256-67, 2010.
65)  Polgar O, Ierano C, Tamaki A, Stanley B, Ward Y, Xia D, Tarasova N, Robey RW, Bates SE.
Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2.
Biochemistry. 49: 2235-45, 2010.
66)  Dunleavy K, Piekarz RL, Zain J, Janik JE, Wilson WH, O'Connor OA, Bates SE.
New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.
Clin. Cancer Res. 16: 5608-17, 2010.
67)  Annunziata CM, Bates SE.
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.
F1000 Biol Rep. 2, 2010.
68)  Bates SE.
Phase I clinical trials: overcoming barriers.
Clin. Cancer Res. 16: 1709, 2010.
69)  Robey RW, Lin B, Qiu J, Chan LL, Bates SE.
Rapid detection of ABC transporter interaction: Potential utility in pharmacology.
J Pharmacol Toxicol Methods. 63: 217-22, 2010.
70)  Panicker J, Li Z, McMahon C, Sizer C, Steadman K, Piekarz R, Bates SE, Thiele CJ.
Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.
Cell Cycle. 9: 1830-8, 2010.
71)  Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, Gardner ER, Figg WD, Bates SE.
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
Expert Rev Anticancer Ther. 10: 997-1008, 2010.
72)  Bates SE.
Striving to improve outcomes in oncology: unmet expectations in a complex disease.
Clin. Cancer Res. 16: 5950, 2010.
73)  Ivy SP, Bates SE.
Targeting the Journey: From Embryogenesis to Cancer Stem Cell.
Clin Cancer Res. 16: 3105, 2010.
74)  Abraham J, Edgerly M, Wilson R, Chen C, Rutt A, Bakke S, Robey R, Dwyer A, Goldspiel B, Balis F, Van Tellingen O, Bates SE, Fojo T.
A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.
Clin. Cancer Res. 15: 3574-82, 2009.
75)  Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, Bates SE.
ABCG2: a perspective.
Adv. Drug Deliv. Rev. 61: 3-13, 2009.
76)  Polgar O, Ediriwickrema LS, Robey RW, Sharma A, Hegde RS, Li Y, Xia D, Ward Y, Dean M, Ozvegy-Laczka C, Sarkadi B, Bates SE.
Arginine 383 is a crucial residue in ABCG2 biogenesis.
Biochim. Biophys. Acta. 1788: 1434-43, 2009.
77)  Robey RW, Obrzut T, Shukla S, Polgar O, Macalou S, Bahr JC, Di Pietro A, Ambudkar SV, Bates SE.
Becatecarin (rebeccamycin analog, NSC 655649) is a transport substrate and induces expression of the ATP-binding cassette transporter, ABCG2, in lung carcinoma cells.
Cancer Chemother. Pharmacol. 64: 575-83, 2009.
78)  Henrich CJ, Robey RW, Takada K, Bokesch HR, Bates SE, Shukla S, Ambudkar SV, McMahon JB, Gustafson KR.
Botryllamides: Natural Product Inhibitors of ABCG2.
ACS Chem. Biol. 4: 637-47, 2009.
79)  Bates SE, Benz EJ.
Commentary: troublesome words, linguistic precision, and medical oncology.
Oncologist. 14: 445-7, 2009.
80)  Piekarz RL, Bates SE.
Epigenetic modifiers: basic understanding and clinical development.
Clin. Cancer Res. 15: 3918-26, 2009.
81)  Bates SE.
Epigenetic therapies reach main street.
Clin. Cancer Res. 15: 3917, 2009.
82)  Kenneth K, Robey R, Knutsen T, Zhan Z, Ried T, Bates S.
Escape from hsa-miR-519c enables drug resistant cells to maintain high expression of ABCG2.
Mol Cancer Ther. 8: 2959-68, 2009.
83)  Bates SE.
From the Editor.
Clin Cancer Res. 15: 7469-7470, 2009.
84)  Deeken JF, Robey RW, Shukla S, Steadman K, Chakraborty A, Poonkuzhali B, Schuetz EG, Holbeck S, Ambudkar SV, Bates SE.
Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.
Mol. Pharmacol. 76: 946-56, 2009.
85)  Shi Z, Tiwari AK, Shukla S, Robey RW, Kim IW, Parmar S, Bates SE, Si QS, Goldblatt CS, Abraham I, Fu LW, Ambudkar SV, Chen ZS.
Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478.
Biochem. Pharmacol. 77: 781-93, 2009.
86)  Stein WD, Huang H, Menefee M, Edgerly M, Kotz H, Dwyer A, Yang J, Bates SE.
Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma.
Cancer J. 15: 441-7, 2009.
87)  Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE.
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
J. Clin. Oncol. 27: 5410-7, 2009.
88)  Piekarz R, Frye R, Turner M, Wright J, Allen S, Kirschbaum M, Zain J, Prince H, Leonard J, Geskin L, Reeder C, Joske D, Figg W, Gardner E, Steinberg S, Jaffe E, Stetler-Stevenson M, Lade S, Fojo A, Bates S.
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
J Clin Oncol. 27: 5410-7, 2009.
89)  Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, Price DK, Frye R, Piekarz RL, Bates SE, Figg WD.
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
Clin. Cancer Res. 15: 1496-503, 2009.
90)  Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES, Raffeld M, Janik JE, Prince HM, Bates SE.
Reactivation of DNA viruses in association with histone deacetylase inhibitor (HDI) therapy: a case series report.
Haematologica. 94: 1618-22, 2009.
91)  Vidaurre T, Wilkerson J, Simon R, Bates SE, Fojo T.
Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development.
Cancer J. 15: 366-73, 2009.
92)  Shukla S, Robey RW, Bates SE, Ambudkar SV.
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
Drug Metab. Dispos. 37: 359-65, 2009.
93)  Polgar O, Deeken JF, Ediriwickrema LS, Tamaki A, Steinberg SM, Robey RW, Bates SE.
The 315-316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant.
Mol. Cell. Biochem. 322: 63-71, 2009.
94)  Shi Z, Parmar S, Peng XX, Shen T, Robey RW, Bates SE, Fu LW, Shao Y, Chen YM, Zang F, Chen ZS.
The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.
Oncol. Rep. 21: 483-9, 2009.
95)  Polgar O, Robey RW, Bates SE.
ABCG2: structure, function and role in drug response.
Expert Opin Drug Metab Toxicol. 4: 1-15, 2008.
96)  Stein WD, Yang J, Bates SE, Fojo T.
Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.
Oncologist. 13: 1055-62, 2008.
97)  O'Mahony D, Peikarz RL, Bandettini WP, Arai AE, Wilson WH, Bates SE.
Cardiac involvement with lymphoma: a review of the literature.
Clin Lymphoma Myeloma. 8: 249-52, 2008.
98)  Bates SE.
CCR focus: breast cancer.
Clin. Cancer Res. 14: 7987, 2008.
99)  Bates SE.
From the editor.
Clin. Cancer Res. 14: 5663, 2008.
100)  Bates SE.
From the editor.
Clin. Cancer Res. 14: 3657, 2008.
101)  Bates SE.
From the editor. Bridging the gap between biostatistician and oncologist.
Clin. Cancer Res. 14: 5953, 2008.
102)  To KK, Polgar O, Huff LM, Morisaki K, Bates SE.
Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.
Mol. Cancer Res. 6: 151-64, 2008.
103)  Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, Fojo T, Bates SE.
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
Biochem. Pharmacol. 75: 1302-12, 2008.
104)  Bates SE.
New cytotoxics in oncology. From the editor.
Clin. Cancer Res. 14: 1609, 2008.
105)  Robey RW, Lazarowski A, Bates SE.
P-glycoprotein--a clinical target in drug-refractory epilepsy?.
Mol. Pharmacol. 73: 1343-6, 2008.
106)  Steadman K, Stein WD, Litman T, Yang SX, Abu-Asab M, Dutcher SK, Bates S.
PolyHEMA spheroids are an inadequate model for the drug resistance of the intractable solid tumors.
Cell Cycle. 7: 818-29, 2008.
107)  Liao Z, Robey RW, Guirouilh-Barbat J, To KK, Polgar O, Bates SE, Pommier Y.
Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.
Mol. Pharmacol. 73: 490-7, 2008.
108)  To KK, Zhan Z, Litman T, Bates SE.
Regulation of ABCG2 expression at 3'-untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in S1 colon cancer cell line.
Mol Cell Biol. 28: 5147-61, 2008.
109)  Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, Chewning KJ, Wu CP, Varticovski L, Bates SE, Caplen NJ, Ambudkar SV.
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
Br. J. Cancer. 98: 1515-24, 2008.
110)  Stein WD, Figg WD, Dahut W, Stein AD, Hoshen MB, Price D, Bates SE, Fojo T.
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.
Oncologist. 13: 1046-54, 2008.
111)  Stein WD, Litman T, Fojo T, Bates SE.
A database study that identifies genes whose expression correlates, negatively or positively, with 5-year survival of cancer patients.
Biochim. Biophys. Acta. 1770: 857-71, 2007.
112)  Robey RW, Polgar O, Deeken J, To KW, Bates SE.
ABCG2: determining its relevance in clinical drug resistance.
Cancer Metastasis Rev. 26: 39-57, 2007.
113)  Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, Baker SD.
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Cancer Biol. Ther. 6: 432-8, 2007.
114)  Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR, Fu LW, Ambudkar SV, Chen ZS.
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Cancer Res. 67: 11012-20, 2007.
115)  Zhuang SH, Hung YE, Hung L, Robey RW, Sackett DL, Linehan WM, Bates SE, Fojo T, Poruchynsky MS.
Evidence for microtubule target engagement in tumors of patients receiving ixabepilone.
Clin. Cancer Res. 13: 7480-6, 2007.
116)  Piekarz RL, Sackett DL, Bates SE.
Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
Cancer J. 13: 30-9, 2007.
117)  Bates SE, Piekarz RL.
Histone deacetylase inhibitors in combinations: will the preclinical promises be kept?.
Cancer J. 13: 80-3, 2007.
118)  Brendel C, Scharenberg C, Dohse M, Robey RW, Bates SE, Shukla S, Ambudkar SV, Wang Y, Wennemuth G, Burchert A, Boudriot U, Neubauer A.
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.
Leukemia. 21: 1267-75, 2007.
119)  Robey RW, Shukla S, Steadman K, Obrzut T, Finley EM, Ambudkar SV, Bates SE.
Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure.
Mol. Cancer Ther. 6: 1877-85, 2007.
120)  Cramer J, Kopp S, Bates SE, Chiba P, Ecker GF.
Multispecificity of drug transporters: probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2.
ChemMedChem. 2: 1783-8, 2007.
121)  Henrich CJ, Robey RW, Bokesch HR, Bates SE, Shukla S, Ambudkar SV, Dean M, McMahon JB.
New inhibitors of ABCG2 identified by high-throughput screening.
Mol. Cancer Ther. 6: 3271-8, 2007.
122)  Takagi K, Dexheimer TS, Redon C, Sordet O, Agama K, Lavielle G, Pierré A, Bates SE, Pommier Y.
Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.
Mol. Cancer Ther. 6: 3229-38, 2007.
123)  Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, Huff LM, Innocenti F, Das S, Cook EH, Cox NJ, Bates SE, Ratain MJ.
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.
Clin. Cancer Res. 13: 6788-95, 2007.
124)  Telford WG, Bradford J, Godfrey W, Robey RW, Bates SE.
Side population analysis using a violet-excited cell-permeable DNA binding dye.
Stem Cells. 25: 1029-36, 2007.
125)  Fox E, Bates SE.
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.
Expert Rev Anticancer Ther. 7: 447-59, 2007.
126)  Goldsmith ME, Aguila A, Steadman K, Martinez A, Steinberg SM, Alley MC, Waud WR, Bates SE, Fojo T.
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.
Mol. Cancer Ther. 6: 496-505, 2007.
127)  Deeken JF, Figg WD, Bates SE, Sparreboom A.
Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
Anticancer Drugs. 18: 111-26, 2007.
128)  Li YF, Polgar O, Okada M, Esser L, Bates SE, Xia D.
Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study.
J. Mol. Graph. Model. 25: 837-51, 2007.
129)  Henrich CJ, Bokesch HR, Dean M, Bates SE, Robey RW, Goncharova EI, Wilson JA, McMahon JB.
A high-throughput cell-based assay for inhibitors of ABCG2 activity.
J Biomol Screen. 11: 176-83, 2006.
130)  To KK, Zhan Z, Bates SE.
Aberrant promoter methylation of the ABCG2 gene in renal carcinoma.
Mol Cell Biol. 2006.
131)  Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K.
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
Clin. Pharmacol. Ther. 80: 192-201, 2006.
132)  Nesterova MV, Johnson N, Cheadle C, Bates SE, Mani S, Stratakis CA, Kahn I, Gupta RK, Cho-Chung YS.
Autoantibody cancer biomarker: extracellular protein kinase A.
Cancer Res. 66: 8971-4, 2006.
133)  Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, Bates SE.
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.
Clin. Cancer Res. 12: 3762-73, 2006.
134)  Bates SE, Rosing DR, Fojo T, Piekarz RL.
Challenges of evaluating the cardiac effects of anticancer agents.
Clin. Cancer Res. 12: 3871-4, 2006.
135)  Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE.
Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).
Clin. Cancer Res. 12: 1547-55, 2006.
136)  Jamroziak K, Balcerczak E, Smolewski P, Robey RW, Cebula B, Panczyk M, Kowalczyk M, Szmigielska-Kaplon A, Mirowski M, Bates SE, Robak T.
MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia.
Pharmacol Rep. 58: 720-8, 2006.
137)  Polgar O, Ozvegy-Laczka C, Robey RW, Morisaki K, Okada M, Tamaki A, Koblos G, Elkind NB, Ward Y, Dean M, Sarkadi B, Bates SE.
Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization.
Biochemistry. 45: 5251-60, 2006.
138)  Shukla S, Robey RW, Bates SE, Ambudkar SV.
The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2.
Biochemistry. 45: 8940-51, 2006.
139)  Robey RW, Fetsch PA, Polgar O, Dean M, Bates SE.
The livestock photosensitizer, phytoporphyrin (phylloerythrin), is a substrate of the ATP-binding cassette transporter ABCG2.
Res. Vet. Sci. 81: 345-9, 2006.
140)  Sisodiya SM, Bates SE.
Treatment of drug resistance in epilepsy: one step at a time.
Lancet neurology. 5: 380-1, 2006.
141)  Zhuang SH, Agrawal M, Edgerly M, Bakke S, Kotz H, Thambi P, Rutt A, Balis FM, Bates S, Fojo T.
A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.
Cancer. 103: 1932-8, 2005.
142)  Polgar O, Bates SE.
ABC transporters in the balance: is there a role in multidrug resistance?.
Biochem Soc Trans. 33: 241-5, 2005.
143)  Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, Robey RW, Bates SE, Assaraf YG.
ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.
Cancer Res. 65: 8414-22, 2005.
144)  Robey RW, Steadman K, Polgar O, Bates SE.
ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy.
Cancer Biol Ther. 4: 187-94, 2005.
145)  Rao VK, Wangsa D, Robey RW, Huff L, Honjo Y, Hung J, Knutsen T, Ried T, Bates SE.
Characterization of ABCG2 gene amplification manifesting as extrachromosomal DNA in mitoxantrone-selected SF295 human glioblastoma cells.
Cancer Genet Cytogenet. 160: 126-33, 2005.
146)  Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, Bates S, Fojo T.
Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors.
Cancer Res. 65: 7386-92, 2005.
147)  Stein WD, Litman T, Fojo T, Bates SE.
Differential expression of cell adhesion genes: implications for drug resistance.
Int J Cancer. 113: 861-5, 2005.
148)  Stein WD, Litman T, Fojo T, Bates SE.
Differential expression of cell adhesion genes: implications for drug resistance.
Int J Cancer. 113: 861-5, 2005.
149)  Shizukuda Y, Piekarz RL, Bates SE, Sachdev V, Finkel T, Rosing DR.
Effect of a histone deacetylase inhibitor on human cardiac mass.
Cardiovasc Drugs Ther. 19: 89-90, 2005.
150)  Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, Sparreboom A.
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Clin. Cancer Res. 11: 7398-404, 2005.
151)  Bates SE, Fojo T.
Epidermal growth factor receptor inhibitors: a moving target?.
Clin. Cancer Res. 11: 7203-5, 2005.
152)  Ahmed-Belkacem A, Pozza A, Muñoz-Martínez F, Bates SE, Castanys S, Gamarro F, Di Pietro A, Pérez-Victoria JM.
Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
Cancer Res. 65: 4852-60, 2005.
153)  Robbins AR, Jablonski SA, Yen TJ, Yoda K, Robey R, Bates SE, Sackett DL.
Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin.
Cell Cycle. 4: 717-26, 2005.
154)  Fetsch PA, Abati A, Litman T, Morisaki K, Honjo Y, Mittal K, Bates SE.
Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues.
Cancer Lett. 2005.
155)  Morisaki K, Robey RW, Ozvegy-Laczka C, Honjo Y, Polgar O, Steadman K, Sarkadi B, Bates SE.
Single nucleotide polymorphisms modify the transporter activity of ABCG2.
Cancer Chemother Pharmacol. 56: 161-72, 2005.
156)  Rao VK, Knutsen T, Ried T, Wangsa D, Flynn BM, Langham G, Egorin MJ, Cole D, Balis F, Steinberg SM, Bates S, Fojo T.
The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration.
Mutat. Res. 583: 105-19, 2005.
157)  Dean M, Fojo T, Bates S.
Tumour stem cells and drug resistance.
Nat Rev Cancer. 5: 275-84, 2005.
158)  Dong D, Ko B, Baumeister P, Swenson S, Costa F, Markland F, Stiles C, Patterson JB, Bates SE, Lee AS.
Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment.
Cancer Res. 65: 5785-91, 2005.
159)  Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B, Stein WD, Choyke P, Balis F, Figg WD, Fojo T.
A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.
Clin. Cancer Res. 10: 4724-33, 2004.
160)  Piekarz R, Bates S.
A review of depsipeptide and other histone deacetylase inhibitors in clinical trials.
Curr. Pharm. Des. 10: 2289-98, 2004.
161)  Stein WD, Litman T, Fojo T, Bates SE.
A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins.
Cancer Res. 64: 2805-16, 2004.
162)  Bates SE, Medina-Pérez WY, Kohlhagen G, Antony S, Nadjem T, Robey RW, Pommier Y.
ABCG2 Mediates Differential Resistance to SN-38 (7-Ethyl-10-hydroxycamptothecin) and Homocamptothecins.
J Pharmacol Exp Ther. 310: 836-42, 2004.
163)  Alqawi O, Bates S, Georges E.
Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding.
Biochem J. 382: 711-6, 2004.
164)  Xu J, Liu Y, Yang Y, Bates S, Zhang JT.
Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2.
J Biol Chem. 279: 19781-9, 2004.
165)  Hwang K, Piekarz RL, Bates SE, Figg WD, Sparreboom A.
Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci. 809: 81-6, 2004.
166)  Hwang K, Piekarz RL, Bates SE, Figg WD, Sparreboom A.
Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci. 809: 81-6, 2004.
167)  Mertins SD, Myers TG, Holbeck SL, Medina-Perez W, Wang E, Kohlhagen G, Pommier Y, Bates SE.
In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity.
Mol Cancer Ther. 3: 849-60, 2004.
168)  Polgar O, Robey RW, Morisaki K, Dean M, Michejda C, Sauna ZE, Ambudkar SV, Tarasova N, Bates SE.
Mutational analysis of ABCG2: role of the GXXXG motif.
Biochemistry. 43: 9448-56, 2004.
169)  Martin CM, Meeson AP, Robertson SM, Hawke TJ, Richardson JA, Bates S, Goetsch SC, Gallardo TD, Garry DJ.
Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart.
Dev Biol. 265: 262-75, 2004.
170)  Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, Bates SE.
Pheophorbide a is a specific probe for ABCG2 function and inhibition.
Cancer Res. 64: 1242-6, 2004.
171)  Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH, Torrico S, Bates SE.
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.
Blood. 103: 4636-43, 2004.
172)  Ujhelly O, Ozvegy C, Várady G, Cervenak J, Homolya L, Grez M, Scheffer G, Roos D, Bates SE, Váradi A, Sarkadi B, Német K.
Application of a human multidrug transporter (ABCG2) variant as selectable marker in gene transfer to progenitor cells.
Human Gene Ther. 14(4): 403-412, 2003.
173)  Agrawal M, Abraham J, Balis FM, Edgerly M, Stein WD, Bates S, Fojo T, Chen CC.
Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.
Clin Cancer Res. 9(2): 650-6, 2003.
174)  Stein WD, Robey R, Cardarelli C, Gottesman MM, Bates SE.
Low and high concentrations of the Topo II inhibitor daunorubicin in NIH3T3 cells reversible G2/M versus irreversible G1 and S arrest.
Cell Cycle. 2(2): A11-A19, 2003.
175)  Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, Bates SE.
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity.
Br J Cancer. 89: 1971-8, 2003.
176)  Fojo T, Bates S.
Strategies for reversing drug resistance.
Oncogene. 22: 7512-23, 2003.
177)  Goldsmith ME, Kitazono M, Fok P, Aikou T, Bates S, Fojo T.
The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells.
Clin Cancer Res. 9: 5394-401, 2003.
178)  Leonard GD, Fojo T, Bates SE.
The role of ABC transporters in clinical practice.
Oncologist. 8(5): 411-24, 2003.
179)  Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD.
Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport.
Cancer Res. 63: 4048-54, 2003.
180)  Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, Bartlett D, Choyke P, Robey R, Hung E, Steinberg SM, Bates S, Fojo T.
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma.
Cancer. 94(9): 2333-2343, 2002.
181)  Bishop PC, Myers T, Robey R, Fry D, Liu ET, Bates SE.
Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.
Oncogene. 21(1): 119-127, 2002.
182)  Kitazono M, Rao VK, Robey R, Aikou T, Bates S, Fojo T, Goldsmith ME.
Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells.
Blood. 99(6): 2248-2251, 2002.
183)  Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, Bates SE.
Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity.
Molec Cancer Therap. 1: 937-941, 2002.
184)  Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, Bates SE, Thiele CJ.
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
Cancer Res. 62(21): 6108-6115, 2002.
185)  Gottesman MM, Fojo T, Bates SE.
Multidrug resistance in cancer: role of ATP-dependent transporters.
Nature Rev Cancer. 2(1): 48-58, 2002.
186)  Sandor V, Bakke S, Robey R, Kang MH, Blagaskonny M, Brooks R, Piekarz R, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE.
Phase I trial of a novel antitumor depsipeptide (FR901228) in patients with refractory neoplasms.
Clin Cancer Res. 8: 718-728, 2002.
187)  Bates SE, Chen C, Robey R, Kang M, Figg WD, Fojo T.
Reversal of multidrug resistance: lessons from clinical oncology.
Novartis Found Symp. 243: 283-296, 2002.
188)  Honjo Y, Morisaki K, Huff LM, Robey RW, Hung J, Dean M, Bates SE.
Single-Nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1).
Cancer Biol & Therap. 1(6): 696-702, 2002.
189)  Kitazono M, Bates S, Fok P, Fojo T, Blagosklonny MV.
The histone deacetylase inhibitor FR901228 (depsipeptide) restores expression and function of pseudo-null p53.
Cancer Biol Therap. 1(6): 665-668,, 2002.
190)  Litman T, Jensen U, Hansen A, Covitz KM, Zhan Z, Fetsch P, Abati A, Hansen PR, Horn T, Skovsgaard T, Bates SE.
Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BXRABCPABCG2.
Biochimica et Biophysica Acta. 1565: 6-16, 2002.
191)  Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, Bates S.
A Phase I Study of Infusional Paclitaxel in Combination with the PgP Antagonist PSC833.
J Clin Oncol. 19(3): 832-842, 2001.
192)  Bates S, Kang M, Meadows B, Bakke S, Choyke P, Merino M, Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, Figg W, Fojo T.
A Phase I Study of Infusional Vinblastine in Combination with the P-glycoprotein Antagonist PSC 833 (Valdospar).
Cancer. 92: 1577-90, 2001.
193)  Honjo Y, Hrycyna CA, Yan QW, Medina-Pérez WY, Robey RW, van de Laar A, Litman T, Dean M, Bates SE.
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Cancer Res. 61(18): 6635-6639, 2001.
194)  Kang MH, Figg WD, Ando Y, Blagosklonny MV, Liewehr D, Fojo T, Bates SE.
The p-glycoprotein antagonist psc 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
Clin Cancer Res. 7: 1610-1617, 2001.
Click Here to View Collapsed Bibliography.

This page was last updated on 6/30/2014.